KOSDAQBiotech & Pharma244460

Olipass

₩1,651 0.00%2026-11-18 close
Market Cap
₩13.4B
Turnover
₩0
Volume
0 shares
Shares out.
8.1M
PER
—
PBR
—
EPS
-₩657
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Olipass: Capital Erosion and Listing Procedures Come First

Olipass disclosed full capital impairment as of June 30, 2026, and its delisting decision remains under an injunction process, so listing status and capital structure matter more right now than business milestones.

  1. 1

    Full capital impairment was disclosed as of June 30, 2026, and first-quarter 2026 sales below KRW 300 million added a listing-eligibility review reason.

  2. 2

    Annual operating loss narrowed from KRW 24.1 billion in 2022 to KRW 7.39 billion in 2025, while the 2025 net loss attributable to controlling shareholders widened to KRW 15.4 billion.

  3. 3

    Second-quarter 2026 sales of KRW 1.17 billion were driven mainly by technology export revenue, and third-quarter sales fell back to KRW 17.6 million.

  4. 4

    After the October 2025 delisting decision, the injunction proceedings have kept follow-up procedures such as the clearing sale on hold.

  5. 5

    Private placements totaling KRW 57.5 billion and a 10-to-1 free capital reduction have progressively diluted minority shareholders.

02

Business structure

Olipass is an RNA therapeutics developer founded in November 2006, and it positions its proprietary OliPass PNA (peptide nucleic acid) platform as its core technology. The platform has been presented as strong in binding target RNA and in cell permeability.

Its basic strategy applies the exon skipping principle to suppress production of disease-causing proteins. Its lead pipeline, the non-opioid pain killer OLP-1002, drew attention in 2020 when Australian Phase 1b approval was reported, and a hyperlipidemia candidate was presented at preclinical stage in the same period.

Early on, a cosmetics subsidiary, Olipass Cosmeceuticals, launched products on home shopping channels in December 2019 to broaden revenue.

However, the second-quarter 2026 revenue mix, as compiled by Butler company data, was 96% technology export and 4% rental income, so revenue depends heavily on technology transfer contracts. Platform-based joint research with global pharmaceutical companies is reported as ongoing.

In competition, OliX Pharmaceuticals and other domestic firms have entered RNA therapeutics, while Biogen, Pfizer and Roche have made technology transfer deals in the same field. No pipeline asset moving into commercialization has yet appeared in reported results. The company had 26 employees as of October 3, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩100M-₩1.5B−1246.6%
2025Q4₩100M-₩1.7B−1290.4%
2026Q1₩91,366,355-₩1.8B−1958.0%
2026Q2₩1.2B-₩100M−10.0%
2026Q3₩17,600,000-₩1B−5800.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.3B-₩24.1B-₩24.2B−1050.9%−231.0%170.3%
2023₩5.3B-₩13.7B-₩12.9B−259.1%−519.3%445.8%
2024₩800M-₩10.1B-₩5.3B−1338.5%−44.8%121.6%
2025₩800M-₩7.4B-₩15.4B−905.6%−905.0%917.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

On a disclosed annual basis, sales rose from KRW 2.3 billion in 2022 to KRW 5.29 billion in 2023, up 130.4% year on year, making 2023 the largest year of 2022 to 2025. Sales then fell 85.7% to KRW 756 million in 2024, the smallest year, and rose 7.9% to KRW 816 million in 2025.

Sharp swings in sales suggest revenue depends more on contract and technology transfer timing than on product sales. Operating loss narrowed each year, from KRW 24.1 billion in 2022 to KRW 13.7 billion in 2023, KRW 10.1 billion in 2024 and KRW 7.39 billion in 2025.

Operating margin ran at -1,050.9% in 2022, -259.1% in 2023, -1,338.5% in 2024 and -905.6% in 2025, with large swings because the sales base is small. Net loss attributable to controlling shareholders shrank from KRW 24.2 billion in 2022 to KRW 5.32 billion in 2024, then widened to KRW 15.4 billion in 2025.

The 2025 net loss including non-controlling interests was also KRW 15.4 billion, so minority interest effects are not visible on an annual basis. Operating cash outflow narrowed from -KRW 15.5 billion in 2022 to -KRW 6.81 billion in 2025.

At the end of 2025, total equity was KRW 1.7 billion, all attributable to controlling shareholders, against total liabilities of KRW 15.6 billion. The debt-to-equity ratio was 170.3% in 2022, 445.8% in 2023 and 121.6% in 2024, then jumped to 917.8% in 2025.

Quarterly sales went from KRW 124 million in the third quarter of 2025 and KRW 129 million in the fourth quarter to KRW 91.37 million in the first quarter of 2026, then KRW 1.17 billion in the second quarter, up 1,178.5% from the prior quarter.

The second-quarter operating loss narrowed to KRW 117 million alongside that revenue spike, and since technology export made up 96% of the quarter's revenue per Butler's compilation, the revenue looks largely one-off.

Third-quarter sales fell 98.5% to KRW 17.6 million, and the operating loss widened to KRW 1.02 billion. Net losses attributable to controlling shareholders were KRW 1.92 billion, KRW 570 million and KRW 1.23 billion in the first three quarters of 2026, and the last four quarters total KRW 5.36 billion.

Operating losses have continued for five straight quarters from the third quarter of 2025 through the third quarter of 2026.

05

Industry analysis

RNA therapeutics block production of disease-causing proteins at the gene expression stage, which is described as a step beyond small molecules or antibodies that act on proteins already formed.

A 2020 securities research report named delivery of therapeutic molecules accurately into cells as the field's biggest difficulty. The same report cited a 2018 estimate that biopharmaceuticals accounted for 25% of the total drug market in 2017.

Overseas, Biogen, Pfizer and Roche have signed technology transfer deals for RNA therapeutic candidates. Domestically, biotech companies including OliX Pharmaceuticals have entered RNA therapeutics, raising competitive intensity.

Olipass highlighted cell permeability as a strength, but the same report pointed to clinical success of its own pipeline as the key driver of growth. Per Alphasquare's annual data for 89 companies in the life sciences and engineering sector, average sector sales were KRW 59.2 billion versus KRW 800 million at Olipass.

In the same data, Olipass's debt-to-equity ratio of 917.78% compares with a sector average of 115.23%, ranking second within the sector. Average sector market capitalization of KRW 636.9 billion also shows a wide scale gap. A securities industry source has pointed to a recurring pattern of distress among technology-listed companies.

06

Outlook

The listing procedure will shape the near-term path more than anything else. The KRX Kosdaq Committee resolved to delist Olipass on October 14, 2025, and the company filed for an injunction the next day, which put the clearing sale and other follow-up steps on hold.

In a January 15, 2026 correction filing, the company said the injunction case had been transferred from the Busan District Court Eastern Branch to the Seoul Southern District Court. In an August 14, 2026 notice, KRX said it would proceed with follow-up procedures once the related litigation is decided.

The half-year report filed the same day disclosed full capital impairment as of June 30, 2026, and KRX said this added a listing-eligibility review reason but did not start a separate procedure.

Press reports also said the half-year review came back with a disclaimer of opinion, with the capital impairment ratio given as 117.40%.

In 2024, the impairment ratio exceeded 50% and the stock was designated as an administrative issue, and in June 2024 the largest shareholder changed to Invest Partners No. 1, holding 12.22%, in a third-party rights offering described as aimed at management normalization.

On the business side, the timing of the next pipeline stage and whether new technology transfer deals convert into reported revenue are the next checkpoints. The next periodic report is the 2026 annual report, which will update the annual capital structure and the basis for listing eligibility.

07

Valuation

PER
—
PBR
—
ROE
-8931.2%
EPS
-₩657
BPS
—
Dividend per share
₩0

Olipass has posted net losses over the last four quarters, so no PER can be calculated, and it pays no dividend, so yield-based comparison does not apply.

Full capital impairment disclosed as of June 30, 2026 places equity in negative territory, which limits the usefulness of price-to-book comparisons with its past band or the sector average.

Comparing market capitalization with the sector average shows a much smaller scale, and sector average price-to-book includes negative values, which makes straight comparison difficult. The debt-to-equity ratio is several times the sector average, so capital structure is the main variable in valuation at this stage.

June 2026 reports described the shares as suspended, and because the delisting procedure is on hold, the resumption of trading and the timing of the clearing sale will determine how the quoted price can be compared. Past PER bands carry limited meaning because the loss period has been long.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Platform technology and transfer experience

The OliPass PNA platform is presented as strong in cell permeability and target RNA binding. OLP-1002 received Australian Phase 1b approval reported in 2020. Technology export accounted for 96% of second-quarter 2026 revenue, showing platform contracts can translate into sales. Whether that revenue recurs will depend on future contract disclosures.

Narrowing operating loss and cash outflow

Operating loss narrowed from KRW 24.1 billion in 2022 to KRW 7.39 billion in 2025. Operating cash outflow also shrank from -KRW 15.5 billion in 2022 to -KRW 6.81 billion in 2025. The operating loss reached KRW 117 million in the second quarter of 2026. The third-quarter widening back to KRW 1.02 billion is the point to watch alongside this trend.

Procedural hold and shareholder restructuring

An injunction application against the delisting decision has put the clearing sale and other follow-up steps on hold. Until a court decision, the shares remain in a listed state under this procedure.

In June 2024 the largest shareholder changed to Invest Partners No. 1 with 12.22%, in a third-party rights offering disclosed as aimed at management normalization. Whether the capital-raising direction leads to actual financial improvement is the key question.

09

Bear factors

Deteriorating capital structure

Full capital impairment as of June 30, 2026 was disclosed in the half-year report. At the end of 2025, total equity was KRW 1.7 billion against total liabilities of KRW 15.6 billion, and the debt-to-equity ratio rose to 917.8% from 121.6% in 2024.

The impairment ratio exceeded 50% in 2024, when the stock was designated as an administrative issue. Press reports also said the half-year review carried a disclaimer of opinion.

Listing requirements and revenue gaps

First-quarter 2026 sales below KRW 300 million added a listing-eligibility review reason. Third-quarter 2026 sales fell 98.5% from the prior quarter to KRW 17.6 million. The October 2025 delisting decision leaves the listing status uncertain until a court ruling. If revenue clusters around transfer timing, quarterly gaps could recur.

Repeated financing and shareholder dilution

After raising KRW 14 billion in its IPO, the company raised a total of KRW 57.5 billion through private placements, about four times the IPO size. Repeated free capital reductions and third-party rights offerings have brought total shares outstanding to 8,160,269.

The KRW 5.36 billion net loss attributable to controlling shareholders over the last four quarters shows a continued need for funding. Minority shareholder stakes have been diluted cumulatively.

10

Risk factors

Listing and legal risk

Depending on the injunction ruling, delisting procedures could resume. KRX has said it will proceed with follow-up steps once the litigation is decided. Transfers between courts leave the timing of a ruling uncertain. The outcome will determine whether trading resumes or a clearing sale is scheduled.

Financial and audit risk

Full capital impairment as of June 30, 2026 and a disclaimer in the half-year review remain open issues. The 2026 annual report will carry the audit result alongside the capital structure. If the impairment is not resolved, additional listing-related reasons could continue. With a debt-to-equity ratio of 917.8%, financing pressure rises if cash generation remains limited.

Revenue structure and dilution risk

The second-quarter 2026 revenue spike looks largely one-off given that technology export made up 96% of the quarter. The fall to KRW 17.6 million in the third quarter shows the fragility of this structure. If further capital raises occur while losses continue, existing shareholders could be diluted again. If pipeline results do not convert into reported revenue, the timing of a better revenue structure will slip.

11

What to watch next

  1. Court decision date undetermined (after November 2026)

    The court ruling on the injunction. Depending on the outcome, follow-up delisting steps such as the clearing sale could resume, or the listing status may be settled.

  2. End of March 2027 (annual report filing deadline)

    Confirmed 2026 annual results and the audit opinion in the 2026 annual report. The key points are whether full capital impairment has been resolved and whether listing-eligibility reasons remain.

  3. After the court decision (date undetermined)

    KRX follow-up review procedures and the schedule for trading resumption or the clearing sale. These determine whether the quoted price reflects normal trading.

  4. Quarters following the 2026 annual report (date undetermined)

    Technology transfer contract disclosures and pipeline clinical timelines. Whether sales spikes like the second quarter of 2026 recur, and how the operating loss ratio moves, are the points to check.

12

Overall view

Olipass is an RNA therapeutics developer with a proprietary platform, but on a disclosed basis operating losses and net losses attributable to controlling shareholders have continued every year from 2022 through 2025.

The operating loss narrowed from KRW 24.1 billion in 2022 to KRW 7.39 billion in 2025, yet the net loss attributable to controlling shareholders widened to KRW 15.4 billion in 2025.

In the second quarter of 2026, a technology export-driven KRW 1.17 billion in sales narrowed the loss, while third-quarter sales fell to KRW 17.6 million and the operating loss widened to KRW 1.02 billion.

On the financial side, full capital impairment was disclosed as of June 30, 2026, and the debt-to-equity ratio of 917.8% makes the capital structure the largest burden.

On the listing side, an injunction process has followed the October 2025 delisting decision, and a review reason was added based on first-quarter sales.

Strengths include the platform, technology transfer experience and a narrowing loss trend, while weaknesses include capital impairment, the listing procedure and repeated dilution. The next checkpoints are the court ruling and the audit opinion in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.tradingview.com
  2. thinkpool.com
  3. thinkpool.com
  4. butler.works
  5. thevc.kr
  6. ssl.pstatic.net
  7. ssl.pstatic.net
  8. pharm.edaily.co.kr
  9. securities.miraeasset.com
  10. pharm.edaily.co.kr
  11. markets.hankyung.com
  12. alphasquare.co.kr
  13. vegannews.co.kr
  14. m.news.nate.com
  15. topstarnews.net
  16. news.dealsitetv.com
  17. m.news.nate.com
  18. kind.krx.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis